Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Seen As Concentrated Market For Vaccine Production

This article was originally published in PharmAsia News

Executive Summary

India's vaccine market is being looked upon by the pharmaceutical industry as more attractive as companies begin to look to the nation as a production source. Novartis of Switzerland already has a major investment in producing vaccines in India, including a facility dedicated to human rabies vaccines. Market analysts estimate vaccines as a market in India worth $665 million in the past year, growing at the rate of 20 percent a year. India counts six essential vaccines as part of its national immunization program. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071171

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel